Ratings Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Real-time Estimate Cboe BZX Other stock markets 01:18:00 2024-04-24 pm EDT			5-day change	1st Jan Change
8.22 ^USD	-1.08%		+7.32%	-28.23%

Mar. 28	Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	CI
Feb. 29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's attractive earnings multiples are brought to light by a P/E ratio at 10.7 for the current year.
The company has a low valuation given the cash flows generated by its activity.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
IRONWOOD PHARMACEUTICALS, INC.	-28.23%	1.3B	B
IQVIA HOLDINGS INC.	+3.41%	43.43B	B
LONZA GROUP AG	+47.81%	41.69B	A
MODERNA, INC.	+8.12%	41.31B	B-
CELLTRION, INC.	-10.92%	27.14B	C
ICON PUBLIC LIMITED COMPANY	+8.33%	25.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.52%	18.47B	B
MEDPACE HOLDINGS, INC.	+29.47%	12.59B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.14%	12.33B	C+
UNITED THERAPEUTICS CORPORATION	+8.80%	11.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes